We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. GSK plc (NYSE:GSK) is one of the most undervalued stocks in the pharma sector.
TheFly reported on May 7 that GSK launched a public health awareness initiative under its Ask2BSure campaign, introducing Julie Bowen and Ty Burrell as campaign advocates to promote education around meningococcal disease, also known as meningitis. The effort encourages parents to better understand infection risks and discuss vaccination with healthcare providers.
The campaign includes an educational video titled The Mening-Itinerary, which illustrates everyday teen environments such as dorms, gyms, and social gatherings where bacterial transmission may occur. The content also highlights survivor experiences and aims to address gaps in parental awareness about disease risk and prevention. The initiative is designed to strengthen public understanding of meningitis and support informed vaccination decisions through storytelling and outreach.
Expanding its global commercial footprint, on May 11, GSK plc (NYSE:GSK) entered into an exclusive strategic collaboration with Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group to accelerate the launch and commercialization of bepirovirsen in mainland China. Bepirovirsen is an investigational first-in-class therapy for chronic hepatitis B and is currently under priority regulatory review in China. The partnership combines GSK’s research and development capabilities with CTTQ’s established liver disease franchise and extensive hospital access network across thousands of medical centers.
Under the agreement, CTTQ will manage importation, distribution, and promotional activities in China, while GSK retains global regulatory, safety, and medical oversight responsibilities. The collaboration also includes potential evaluation of select early-stage assets for future partnership opportunities beyond China.
GSK plc (NYSE:GSK) is a global biopharma company headquartered in London. It develops medicines and vaccines, with a focus on infectious diseases, HIV, respiratory and immunology conditions, and oncology.
While we acknowledge the risk and potential of GSK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GSK and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 12 Best Strong Buy Tech Stocks to Invest In Now and 10 Most Widely Held Stocks by Individuals in 2026 .
Disclosure: None. Follow Insider Monkey on Google News.
